Novo Nordisk

NVO

Market cap $198B

The bulk of Novo Nordisk's sales come from weight-loss and diabetes treatments. The biotech faces competition from companies like Eli Lilly and Pfizer, among others.

Novo Nordisk has had a stellar past month at the stock markets with a 25% rise after it touched multi-year lows earlier this year. Fuelling the rise are oral Ozempic and Wegovy pill launches, alongside FDA approvals and telehealth collaborations. The company even managed to trivially raise sales guidance. With low market multiples, I retain a Buy rating as the company's restructuring efforts are beginning to bear fruit.

NVO beats Q1 estimates and raises its 2026 outlook. Meanwhile, Eli Lilly's expanding GLP-1 portfolio threatens its obesity market dominance.

Novo Nordisk recently posted strong quarterly results. Newer launches are boosting sales.

LLY expands beyond tirzepatide with oral obesity pills and next-gen drugs like retatrutide to defend its lead in the booming weight-loss market.

Novo Nordisk A/S NYSE: NVO said its first quarter of 2026 was marked by rapid uptake of its newly launched Wegovy pill in the U.S., continued expansion of its obesity franchise and a series of pipeline and regulatory milestones, even as adjusted sales declined because of lower realized prices.

Almost a third of adults taking Wegovy® pill (oral semaglutide 25 mg) were early responders to treatment, achieving an average of 13.2% weight loss after four months and 21.6% weight loss at the end of the OASIS 4 clinical trial1. Nearly eight in 10 people with poor physical function who took the Wegovy® pill almost doubled their ability to move, including bending over, standing comfortably and staying active, compared to placebo2.

Novo Nordisk A/S (NYSE:NVO) presented new sub-analyses from its STEP UP clinical trial at the European Congress on Obesity, highlighting that a higher dose of Wegovy helped people with obesity achieve substantial weight loss regardless of how quickly they initially responded to treatment.

With its best-in-breed GLP-1 drugs, Eli Lilly is beginning to cement itself as the dominant player in the massive GLP-1 market.

Bagsværd, Denmark, 12 May 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk.